ZNTL — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• In July 2026, we met with the FDA in a Type D meeting to align on key points related to our accelerated approval strategy, including dose. The FDA had no objection to the continued study of the selected monotherapy dose of azenosertib at 400mg QD 5:2 in patients with Cyclin E1-positive PROC, selecte…

• The integrated dataset of DENALI Parts 2a, 2b, and 2c is designed to support accelerated approval in the Cyclin E1 biomarker-selected patient population, subject to regulatory review. We expect to provide a topline readout of DENALI Part 2 in the first half of 2027 to allow for data maturation post …

• In May 2026, we presented data from Part 1 of the Phase 1b MUIR trial at the ASCO Annual Meeting. The findings reflect a December 1, 2025 data cutoff and include 46 patients who received azenosertib across four dose cohorts — 200 mg QD continuously or 200 mg, 250 mg, or 300 mg QD intermittently (5 d…

• General and administrative expenses for the three months ended June 30, 2026 were $9.2 million, compared to $8.4 million during the three months ended June 30, 2025. This increase of $0.8 million was primarily attributable to an increase of $1.7 million for consulting and outside services. This incr…

• Investment and other income (expense), net was $2.2 million for the three months ended June 30, 2026, compared to $9.2 million for the three months ended June 30, 2025. The decrease of $7.0 million was primarily driven by a non-cash recognized gain of $4.6 million on the mark to market adjustment fo…

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• We expect to complete enrollment in all cohorts of DENALI Part 2 and provide a topline readout of the trial by year-end 2026. The FDA has granted Fast Track Designation to azenosertib for the treatment of patients with Cyclin E1-positive PROC.

• General and administrative expenses for the three months ended March 31, 2026 were $9.1 million, compared to $10.6 million during the three months ended March 31, 2025. This decrease of $1.5 million was attributable to a decrease of $2.0 million in personnel expense, of which $1.2 million was non-ca…

• On January 22, 2025, our Board of Directors approved a strategic restructuring of the Company to support execution of late-stage development for azenosertib, and extend its cash runway beyond a potentially registration-enabling azenosertib data readout from the Company’s DENALI Part 2 study, anticip…

• Restructuring expenses for the three months ended March 31, 2026 were zero, compared to $7.8 million during the three months ended March 31, 2025.

• Investment and other income (expense), net was $2.6 million for the three months ended March 31, 2026, compared to $(2.7) million for the three months ended March 31, 2025. The increase of $5.3 million was primarily driven by a non-cash recognized loss of $7.0 million on the mark to market adjustmen…

Text added vs the prior filing · source: 10-Q · 2026-08-06

• Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our …

• any other product candidate that may be granted fast track designation will receive regulatory approval in the United States. Many product candidates that have received fast track designation have ultimately failed to obtain approval.

• competition for qualified labor and changes in local economic conditions which could increase the cost of manufacturing our product candidates and related materials.

• Although no third party has asserted a claim of patent infringement against us as of the date of this periodic report, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin a…

• of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would

• otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors’ product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including:

• result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.

• Although no third party has asserted a claim of patent infringement against us as of the date of this periodic report, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin a…

• candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve su…